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Background: Influenza is an acute respiratory illness caused by influenza viruses, which occurs in epidemics
worldwide every year. Children are an important target for prevention methods, including vaccination. While
evidence about the decision on whether to vaccinate healthy children is robust, evidence supporting the decision
of which of available vaccines to use remains unclear.
This review will summarize the evidence about the efficacy and safety of the available vaccines for seasonal
influenza licensed in the United States for use in healthy children.
Methods/design: An umbrella systematic review (SR) and network meta-analysis will be conducted of randomized
controlled trials (RCTs). We will search for SRs to identify parallel RCTs evaluating inactive and/or live attenuated
influenza vaccines licensed in the United States for use in healthy children to prevent influenza. Subsequently, we
will update the literature search of the selected SRs to the present time to capture recent controlled studies. To
complement the work focused on harms, we will also select observational studies focusing on post marketing
retrospective studies. Inclusion will not be limited by language, publication date or publication status. To identify
additional candidate studies, we will review the reference lists of the eligible primary studies and narrative reviews;
we will query the expert members of the Advisory Committee on Immunization Practices and review references
from their previous statement. Additionally, we will review the reports from the Institute of Medicine on the
adverse effects of vaccines. Two reviewers will independently determine study eligibility and will extract descriptive,
methodological (using the Cochrane risk of bias tool for RCTs and the Newcastle–Ottawa scale for observational
studies) and efficacy data. When possible, we will conduct meta-analyses and network meta-analyses by combining
indirect and direct comparisons.
We will evaluate heterogeneity using the I2 statistic and the agreement of indirect comparisons and direct
evidence. We will report the Cochrane Q test to determine the statistical significance of heterogeneity.
The overall quality of evidence will be assessed following the GRADE (Grading of Recommendation, Assessment,
Development and Evaluation) approach.
Discussion: Our systematic review will allow patients, clinicians, guideline developers and policy makers to make
evidence-based choices between the two available vaccine options, by providing information regarding benefits
and harms of these types of vaccines.
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Influenza is an acute respiratory illness caused by influ-
enza A or B viruses, which occurs in seasonal outbreaks
worldwide each year, causing substantial morbidity and
mortality—between 3,000 and 49,000 deaths [1] and over
200,000 hospitalizations [2] annually. While the majority
of influenza-related deaths occur among adults aged 65
years and older [1], children are also at risk of severe
disease, particularly those under 5 years of age [3].
Children are the major source for the diffusion of influ-
enza viruses in the community [4,5]. Some studies showed
socioeconomic benefits from influenza vaccination in
healthy children, both for them and their adult household
contacts [6]. For these reasons, much emphasis has been
placed on preventing influenza in children. The adoption
of universal annual influenza vaccination of children could
reduce the burden of influenza illness among vaccinated
children, unvaccinated household and school contacts,
and reduce community transmission, thereby reducing
severe illness among high risk adults [7].
Currently available seasonal influenza vaccines may be
divided into two groups:
 Inactivated influenza vaccines (IIV): These include
subunit vaccines (containing only surface antigens);
split-virion vaccines (in which virus is inactivated
with disrupting agents, yielding surface and internal
antigens); and whole virion inactivated vaccines
(containing whole inactivated viruses). Among these,
only split-virion vaccines are currently licensed in
the United States. Most are administered
intramuscularly; one intradermal preparation is
available. IIV is available from a number of different
manufacturers; age indications for the different
preparations differ. IIV preparations are available for
children as young as six months of age.
 Live-attenuated (cold-adapted) influenza vaccines
(LAIV): These intranasally-administered vaccines
contain virus which can multiply only in the nasal
passages. LAIV is licensed for persons 2 through 49
years old and is recommended for healthy, non-
pregnant individuals who do not have chronic
medical conditions, due to relative lack of data in
the other populations [8].
The Centers for Disease Control and Prevention (CDC)
Advisory Committee on Immunization Practices (ACIP)
[8] and the American Academy of Pediatrics (AAP) [9] rec-
ommend annual influenza vaccination for all children aged
≥6 months. While the evidence supporting the benefits of
vaccinating healthy children to prevent influenza is robust,
the evidence to support the decision on which vaccine
form to use with whom remains unclear; ACIP currently
expresses no preference for one vaccine over the other [5].Study objectives
This systematic review (SR) aims to summarize the evi-
dence concerning the efficacy and safety of US-licensed
seasonal influenza vaccines for healthy children 6-
months through 18-years old. Evidence for the compara-
tive benefits of LAIV and IIV among children 2- through
18-years old will also be examined.
This evidence will help guideline developers, clinicians
and patients in choosing the most suitable vaccine for each
age group based on tradeoffs between harms and benefits.
Methods/design
Considering the availability of multiple well-conducted
SRs addressing this question, we will start by conducting
an umbrella systematic review [10,11] to identify existing
SRs and select the most recent and comprehensive ones.
We will evaluate each systematic review using the
Assessment of Multiple Systematic Reviews (AMSTAR)
criteria [12] particularly emphasizing the quality and
comprehensiveness of the search strategy. We will also
consider their inclusion and exclusion criteria. Subse-
quently, we will update and, if needed, modify the litera-
ture search of the selected SRs to the present time to
capture recent controlled studies (randomized controlled
trials (RCTs) and non-randomized studies). We will search
electronic databases (Ovid Medline, OVID EMBASE,
OVID Cochrane Library, Web of Science, Scopus and Psy-
cInfo) from the last search date stated in the included SRs
through the present time. With input from study investi-
gators with expertise in conducting SRs (MHM, VMM), a
reference librarian (LP) and the first author (GP) will
design and execute these electronic search strategies
using controlled vocabulary and text words. To identify
additional candidate studies, we will review the refer-
ence lists of the eligible primary studies, narrative
reviews and systematic reviews; and we will query the
expert members of the ACIP Influenza Work Group
and review the references from the previous ACIP In-
fluenza Statement. Additionally, we will review the In-
stitute of Medicine (IOM) report on vaccine adverse
effects [13-15] to capture other possible harm evidence.
The two search strategies (for SRs and individual studies)
are given in the Additional file 1.
Eligibility criteria
We will include parallel-design RCTs that compared
LAIV and IIV to each other or to placebo. Eligible trials
must evaluate the efficacy of seasonal influenza vaccines
(not pandemic vaccines) licensed in the United States
and administered as recommended by the ACIP, and
must enroll healthy children (<18 years). We will ex-
clude vaccinations not administered according to ACIP
recommendations (for example, LAIV given to children
under 2 years of age). Evidence concerning adjuvanted
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be excluded.
For evidence of harm, we will select observational
studies focusing on post marketing retrospective studies.
These studies typically have a larger sample size which is
essential to detect rare adverse events caused by the vac-
cine, such as Guillain-Barre syndrome or anaphylaxis,
with incidence less than 10 cases per million [16].
Study selection
Search output will be uploaded into an online reference
management system (DistillerSR, Ottawa, Canada) to
allow fast and transparent processing with better tracking
and real-time evaluation of inter-reviewer agreement
and progress of reviewers. Two reviewers workingxx Potentially relevant
references (RCTs)
identified references by
search (yyyy to present)
Update
xx excluded in full text screening:
Reasons for exclusion:
xx Not the design of interest
xx Not the outcome of interest
xx Not the intervention of interest
xx Not the patient of interest
xx Not a controlled study









Figure 1 Summary of the study selection process.independently will consider the potential eligibility of each
of the abstracts and titles that will result from executing
the search strategy. Reviewers will request the full text
versions of all potentially eligible studies. The full text of
papers on which there is disagreement will also be
retrieved for evaluation. Two reviewers working inde-
pendently will consider the full text reports (all available
versions of each study) for eligibility. The reviewers will
calibrate their judgments using a smaller set of reports.
Subsequently, disagreements will be resolved by consen-
sus; if not possible, by arbitration by a third reviewer.
Agreement will be measured using the kappa or phi statis-
tic, as appropriate (the latter is appropriate when the dis-
tribution of the feature under evaluation is extremely
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included (up to yyyy)
xx Included RCTs
xx RCTs send for verification to the
ACIP committee
xx references for full text
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xx Included RCTs and
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review
e effects is not
 in the RCTs
Figure 2 Network of comparisons, graphic representation.
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We will collect data in predefined electronic forms
designed using the online reference management system.
Two reviewers separately and independently will extract
full descriptions of participants enrolled, the interven-
tions they received (vaccine description, doses, route),
and the measure of outcome.
Outcomes of interest
1. Effectiveness outcomes measures: a. Laboratory-
confirmed influenza infection, confirmed by
polymerase chain reaction or viral culture; b.
Influenza-like illness (ILI) ; c. Medically attended
respiratory illness (MARI); d. Hospitalization; e.
Mortality; f. Medically attended wheezing.
2. Safety outcome measures: a. Fever due to
vaccination; b. Febrile seizures; c. Immediate
hypersensitivity/anaphylaxis; d. Guillain-Barré
syndrome; e. Serious adverse effects.
Quality assessment
To assess the methodological quality of RCTs we will use
the Cochrane risk-of-bias tool assessment [17] to deter-
mine: how the randomization sequence was generated;
how allocation was concealed; whether there were import-
ant imbalances at baseline; which groups were blinded
(patients, care givers, data collectors, outcome assessors,
data analysts); loss to follow-up; whether participants were
analyzed as randomized; and how missing outcome data
were addressed. We will also evaluate the adequacy of the
outcome measurement process. For observational studies
the quality will be assessed using the Newcastle–Ottawa
scale. No scoring system will be derived.
Statistical analysis
Relative comparisons will be quantified by means of the
relative risk (RR) of outcomes with one vaccine form
versus the other. We choose to report relative risk
instead of odds ratio since RR is more intuitive to clini-
cians and patients [1-18]. To pool head-to-head compar-
isons, we will conduct random effects models using the
DerSimonian & Laird method and report point estimates
and 95% confidence interval [19]. We will evaluate het-
erogeneity using the I2 statistic, a measure of the total
variations of study effect sizes due to true heterogeneity
between studies. Considering that thresholds for the in-
terpretation of I2 can be misleading we will analyze its
importance based on magnitude and direction of effects
and strength of evidence for heterogeneity (for example,
P value from the Cochran’s Q test and confidence inter-
vals for I2) [20]. We will report the Cochrane Q test to
determine the statistical significance of heterogeneity.When possible, we will conduct network meta-
analyses by combining indirect and direct evidence. The
network of comparisons is presented graphically in
Figure 2. Due to the small number of comparisons in
this study, we are quite confident that the network will
have at least one pair of treatments being compared
both directly and indirectly. Thus, Lumley’s generalized
linear mixed models will be used [21]. The agreement of
indirect comparisons and direct evidence, that is, the de-
gree of coherence of the network, will be measured and
incorporated in the calculation of the confidence interval
of the pooled estimate. If the incoherence is large and
network meta-analysis is deemed inappropriate, only
estimates from direct evidence will be pooled and
reported. In rare cases in which the network of compari-
sons does not have at least one pair of treatments being
compared both directly and indirectly, we will use
adjusted indirect comparison (AIC) models instead of
generalized linear mixed models [22].
For studies with loss to follow-up, we will apply the
intention-to-treat principle and analyze the initial number
of patients in the group to which they were randomized.
The decision is to preserve randomization benefits in bal-
ancing prognosis of trial arms even if it leads to underesti-
mated effect sizes [23].
Statistical analyses will be conducted using STATA
version 12.0 (StataCorp, College Station, TX, USA) and
R version 2.15.0 (R Foundation for Statistical Comput-
ing, Vienna, Austria).
Subgroup analysis
If sufficient data were available to explore causes of incon-
sistency and subgroup-treatment interactions, we will
construct the following subgroup analyses defined by: a.
Method used for the diagnosis of laboratory confirmed in-
fluenza (PCR versus viral culture versus other); and b. Age
groups (6 to 23 months, 2 to 8 years, 9 to 18 years).
Table 1 Evidence profile
Quality assessment Number of
patients
Effect Quality Importance
Number of studies Design Risk of bias Inconsistency Indirectness Imprecision Other considerations LAIV IIV RR (95% CI) Absolute
Laboratory confirmed influenza (follow-up; assessed with: PCR or viral culture)
Randomized trials ⊕⊕⊕⊕ HIGH CRITICAL
Influenza like illness (follow-up; assessed with)
Randomized trials ⊕⊕⊕⊕ HIGH IMPORTANT
Hospitalization (follow-up; assessed with)
Randomized trials ⊕⊕⊕⊕ HIGH CRITICAL
Medically attended respiratory illness (follow-up; assessed with)
Randomized trials ⊕⊕⊕⊕ HIGH CRITICAL
Fever due to vaccination (follow-up mean, assessed with)
Randomized trials ⊕⊕⊕⊕ HIGH IMPORTANT
Guillain-Barre syndrome (follow-up mean, assessed with)
Observational study ⊕⊕ΟΟ LOW IMPORTANT
Anaphylaxis (follow-up mean, assessed with)
Observational study ⊕⊕ΟΟ LOW CRITICAL
Question: Should LAIV versus IIV be used for influenza?
Settings: healthy children.
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Publication bias will be assessed using the Peters linear
regression of intervention effects on inverse of study
sample size and visual inspection of funnel plots [24].
Author contact
Data extractors will record the author’s contact informa-
tion (name and email address) from RCTs and observa-
tional studies that fulfilled all the eligibility criteria. We will
contact the authors to obtain sufficient details for quality
assessment or missing data. If we do not receive the infor-
mation from the authors we will try to obtain additional
information about the methodological characteristics of
each study by getting access to each study’s protocol. For
industry-sponsored trials we will seek additional informa-
tion from the current license holder. For studies sponsored
by the National Institute of Health we will ask them for the
protocol.
Reporting
This study will be reported in accordance with the recom-
mendations set forth by the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) work-
group [25] and the recommendations developed by the
International Society for Pharmacoeconomics and Out-
comes Research (ISPOR) [26]. We will present evidence
tables for each trial including description of the popula-
tion characteristics, interventions, methodological quality
and main findings.
Evaluating the quality of evidence
The quality of evidence will be assessed following the
GRADE approach. Evidence profiles will be developed
using the software GRADE profiler (GRADEpro) as
shown in Table 1. This evaluation will include factors of
methodological limitations of the studies, such as: overall
quality assessment of the included studies, imprecision,
indirectness, inconsistency, reporting and publication
biases. This will show our confidence in the pooled esti-
mate according to the quality and will be classified as fol-
low: high, moderate, low or very low [27]. Evidence from
observational studies could be upgraded if studies showed
a large effect size, dose response effect or if the plausible
residual confounding is considered to strengthen the asso-
ciation [28]. Unique to judging the quality of evidence in
vaccination studies, we will consider additional factors
suggested by the Strategic Group of Advisory Experts
(SAGE) committee of the World Health Organization
which are upgrading the evidence for a population effect
or evidence of herd immunity [29].
Discussion
This network meta-analysis aims at synthesizing the avail-
able direct and indirect evidence on the effectiveness andsafety of the different vaccines for seasonal influenza in
healthy children currently available in the United States.
This meta-analysis will allow patients, physician, guideline
developers and policy makers to make evidence based
choices between the two available vaccine options.
Limitations and strengths of this study
We will depend on existing SRs to identify individual
studies published prior to the date of our search update.
Therefore, the comprehensiveness of this SR will depend
in part on that of the published SRs. The existing reviews
we identified through a preliminary search of the literature
seem quite comprehensive (adequate according to the
AMSTAR assessment [10]) and include some published
by the Cochrane Collaboration [30]. However, we are also
supplementing the search strategy by querying experts
and reviewing previous ACIP statements and IOM reports
to reduce the risk of missing relevant studies.
It is plausible that the variation of influenza strain and
virulence from year to year or the matching between the
vaccine and the circulating strain will vary across studies.
Therefore, the network method of pooling direct and in-
direct estimates may be associated with a higher level of
inconsistency/heterogeneity. In this case, we will abandon
the network meta-analysis approach and only use head-
to-head RCTs pooled in a traditional random effects
model meta-analysis.
These criteria were adopted to provide direct evidence
for the comparative effectiveness of contemporary vac-
cines administered in the United States. The evidence
will be less directly applicable to other geographic loca-
tions or settings in which the vaccines are administered
in a way inconsistent with the ACIP statement.
Systematic review status
The systematic review is currently in the data extraction
and preliminary analysis phase. We expect completion
by October 2012.
Additional file
Additional file 1: Search strategies for systematic reviews and
individual studies.
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